Avicanna Inc - Asset Resilience Ratio
Avicanna Inc (AVCN) has an Asset Resilience Ratio of 0.00% as of December 2021. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read AVCN liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2021)
This chart shows how Avicanna Inc's Asset Resilience Ratio has changed over time. See AVCN net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Avicanna Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Avicanna Inc market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 0% |
| Short-term Investments | CA$0.00 | 0% |
| Total Liquid Assets | CA$0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Avicanna Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Avicanna Inc Industry Peers by Asset Resilience Ratio
Compare Avicanna Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC |
Drug Manufacturers - Specialty & Generic | 43.05% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867 |
Drug Manufacturers - Specialty & Generic | 1.96% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Guobang Pharma Ltd
SHG:605507 |
Drug Manufacturers - Specialty & Generic | 8.47% |
Annual Asset Resilience Ratio for Avicanna Inc (2017–2021)
The table below shows the annual Asset Resilience Ratio data for Avicanna Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2021-12-31 | 0.00% | CA$0.00 ≈ $0.00 |
CA$22.30 Million ≈ $16.13 Million |
-- |
| 2020-12-31 | 4.15% | CA$1.25 Million ≈ $904.23K |
CA$30.16 Million ≈ $21.81 Million |
-- |
| 2019-12-31 | 0.00% | CA$0.00 ≈ $0.00 |
CA$45.16 Million ≈ $32.67 Million |
-- |
| 2018-12-31 | 0.00% | CA$0.00 ≈ $0.00 |
CA$28.18 Million ≈ $20.39 Million |
-- |
| 2017-12-31 | 0.47% | CA$10.00K ≈ $7.23K |
CA$2.12 Million ≈ $1.53 Million |
-- |
About Avicanna Inc
Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for consumer, medical, and pharmaceutical markets in Canada and internationally. It provides medical cannabis formulary products, including oral, sublingual, topical, and transdermal deliveries with vari… Read more